Trial Profile
A multiple-dose crossover study of Patiromer in healthy subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 May 2016
Price :
$35
*
At a glance
- Drugs Patiromer (Primary)
- Indications Hyperkalaemia
- Focus Pharmacodynamics
- 28 Dec 2016 New analyses of data from this and another phase I trial (CT profile 268635) were presented at the National Kidney Foundation (NKF) 2016 Spring Clinical Meeting, according to a Relypsa Inc. media release.
- 28 Apr 2016 Results of new analyses from this and another phase I trial (CT profile 268635) published in a Relypsa Inc. media release.
- 21 Apr 2016 According to Relypsa media release, data will be presented at National Kidney Foundation 2016 Spring Clinical Meetings.